GlyTherix Ltd is pleased to advise it has appointed Atoll Financial Group as its financial advisor for its Series B raise of up to USD50M. This round will enable the company to push forward its targeted radiotherapy program Phase 1b trial and includes funding for its subsequent US based Phase 2 trial. GlyTherix looks forward to a long-term partnership with Atoll to further advance and develop its portfolio of first-in-class oncology assets.
GlyTherix appoints Atoll Financial Group as financial advisor for its Series B raise of up to USD50M
